Tango Therapeutics Surges 32% After Phase Trial Data Shows Strong Efficacy
Tango Therapeutics (TNGX) shares surged approximately 32 percent after releasing positive clinical trial data showing meaningful efficacy for its lead oncology candidate.
Read the full story on market.news
🇺🇸 United States Stocks Breaking biotech oncology clinical-trial
What is your take? Drop your thoughts below. 